Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$73.78 USD
+0.40 (0.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
+0.40 (0.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
Cencora (COR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Reasons to Add Merit Medical (MMSI) to Your Portfolio Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Nevro's (NVRO) SCS Therapy Gets Positive Coverage Update
by Zacks Equity Research
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth
by Zacks Equity Research
Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.
Charles River's (CRL) New Launch to Boost Gene Therapy Programs
by Zacks Equity Research
Charles River's (CRL) latest offering is likely to complete a comprehensive range of off-the-shelf plasmid products and simplify gene therapy supply chains with immediate availability.
DexCom's (DXCM) G7 Links With Tandem's Insulin Pump in Europe
by Zacks Equity Research
Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
Masimo (MASI) Gains on Favorable Ruling in Apple Watch Dispute
by Zacks Equity Research
Masimo (MASI) rides on the continuation of the import ban on certain models of Apple watches using disputed blood oxygen sensors.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.
ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.
Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results
by Zacks Equity Research
Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.
Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
Veeva Systems (VEEV) Offerings Adopted by SK Life Science
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand
by Zacks Equity Research
Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.
Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View
by Zacks Equity Research
Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.